Current Recommendations for Nebulizer Therapy in Chronic Respiratory Conditions

Background and Definition

The British Thoracic Society and European Respiratory Society recommend conventional nebulizer therapy for specific situations in chronic respiratory conditions, particularly during acute exacerbations when patients are severely breathless or cannot effectively use metered-dose inhalers 1, 2, 3

Nebulized bronchodilator therapy is indicated in a small number of patients with bronchiectasis, with evaluation criteria similar to those for patients with asthma and COPD 1
For patients with COPD, nebulized salbutamol (2.5-5 mg) or terbutaline (5-10 mg) or ipratropium bromide (500 μg) should be given 4-6 hourly for 24-48 hours during acute exacerbations 4
Combined nebulized treatment (β-agonist with ipratropium bromide) should be considered in more severe cases of COPD exacerbation 4, 3

Patients should undergo formal assessment by a respiratory specialist before prescribing home nebulizer therapy, including review of diagnosis and peak flow monitoring 4, 3
A 15% improvement in peak flow over baseline should be demonstrated before recommending long-term nebulizer therapy 4
The European Respiratory Society emphasizes proper inhaler technique must be demonstrated and checked periodically before changing or modifying inhaled treatments 3

For patients with chronic respiratory conditions, current guidelines strongly recommend metered-dose inhalers (MDIs) with spacers as the first-line non-powder inhaler option for most patients with COPD 3
Long-acting muscarinic antagonists compared with short-acting muscarinic antagonists to prevent acute exacerbations in moderate to severe COPD 8
Maintenance combination inhaled corticosteroid/long-acting β2-agonist therapy compared with long-acting β2-agonist monotherapy to prevent acute exacerbations 8
Consideration of macrolide therapy in specific populations to reduce exacerbation frequency in adults with asthma and other respiratory conditions 5, 6

If considering any nebulizer therapy for patients with carbon dioxide retention and acidosis, the nebulizer should be driven by air, not oxygen 4, 3
Patients should be changed to hand-held inhalers as soon as their condition stabilizes after an acute exacerbation 3